GenrAb Raises $5.6M in Seed Funding for Development of Neuroprotective Therapies
GenrAb, a Dallas, TX-based company specializing in the development of neuroprotective therapies, has secured $5.6 million in Seed funding.
The funding round was led by Actium Group.
GenrAb plans to utilize the investment to expedite the progress of its primary candidate, TGM-010, which is a novel neuroprotective antibody that is fully human.
Headed by CEO Larry Tiffany, GenrAb is focused on the research and creation of neuroprotective and neurotherapeutic human antibodies. Using its unique immunogenetic models, the company analyzes cerebrospinal fluid from patients with active neurological conditions to extract new human antibodies associated with diseases. These antibodies, including TGM-010, are chosen based on their ability to protect neurons and their potential to manage neuronal stress, thereby preserving cell function and viability. Through this innovative approach, GenrAb is establishing a portfolio of patented therapeutic antibodies that can effectively reduce disability in individuals suffering from neurodegenerative disorders. This effort aims to make rare antibodies, typically only found in specific patients with neurological illnesses, more widely accessible.
FinSMEs
22/04/2025
